Enterprise of Rosatom State Corporation
Back to website

Industry news


ANSTO National Medical Facility to Triple Production of Radiopharmaceuticals

ANM project at ANSTO will benefit the Australian health industry and position Australia as a global leader in the high-end manufacturing of nuclear medicine. Through this project, Australia will be able to triple production of molybdenum-99 (Mo-99). ANSTO currently delivers the equivalent of 10,000 patient doses of Mo-99 across Australia each week. The ANM Project includes a nuclear medicine manufacturing plant and a waste treatment plant to treat by-products for permanent, safe storage at a national waste repository. The project is worth $168.8 million and subject to required approvals the plant will be operational from 2016.

Click here to read full article: www.ansto.gov.au

comments powered by Disqus